Khedr Anwar, Mahmoud Esraa Elaraby, Attallah Noura, Mir Mikael, Boike Sydney, Rauf Ibtisam, Jama Abbas B, Mushtaq Hisham, Surani Salim, Khan Syed A
Department of Internal Medicine, BronxCare Health System, Bronx, NY 10457, United States.
Department of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
World J Clin Cases. 2022 Sep 16;10(26):9192-9206. doi: 10.12998/wjcc.v10.i26.9192.
Gastrointestinal bleeding accounts for a drastic negative impact on the quality of the patients' lives as it requires multiple diagnostic and therapeutic interventions to identify the source of the bleeding. Small bowel bleeding is the least common cause of gastrointestinal bleeding. However, it is responsible for the majority of complaints from patients with persisting or recurring bleeding where the primary source of bleeding cannot be identified despite investigation. A somatostatin analog known as octreotide is among the medical treatment modalities currently used to manage small bowel bleeding. This medication helps control symptoms of gastrointestinal bleeding by augmenting platelet aggregation, decreasing splanchnic blood flow, and antagonizing angiogenesis. In this review article, we will highlight the clinical efficacy of octreotide in small bowel bleeding and its subsequent effect on morbidity and mortality.
胃肠道出血对患者的生活质量产生了极大的负面影响，因为它需要多次诊断和治疗干预来确定出血源。小肠出血是胃肠道出血最不常见的原因。然而，在那些尽管经过检查仍无法确定主要出血源的持续性或复发性出血患者中，小肠出血引发的不适占了大多数。一种名为奥曲肽的生长抑素类似物是目前用于治疗小肠出血的药物治疗方式之一。这种药物通过增强血小板聚集、减少内脏血流量和拮抗血管生成来帮助控制胃肠道出血症状。在这篇综述文章中，我们将重点介绍奥曲肽在小肠出血中的临床疗效及其对发病率和死亡率的后续影响。
